Investment Advisor SP Tulsian is of the opinion that one can exit Elder Pharma at Rs 440.
Tulsian told CNBC-TV18, "Elder Pharma is not a stock where you can just expect a return of about 20-30% in three-six months time. Definitely it is a consistent performer, they have a strong presence in the pharma sector. Their P/E multiple is quite low if I take a forward earning call, probably the share is available too at a P/E multiple of about 11-12 while the general application of the P/E to this sector is about 15. So definitely there is growth potential but in that event, either the investor has to enlarge the holding period maybe six-twelve months instead of three-six months."
He further added, "My advise is remain invested at the time being but think of getting out at around Rs 440 levels because that is the potential the stock is holding to go up in the next three-six months. Definitely, there are better options if you have seen the performance of Biocon, Wockhardt Pharma or maybe other pharmaceutical companies are available in this space. But Elder Pharma is not a bad stock as I have said but they are all less fancied, they are having less exposure by the investors but definitely you have the better place from an appreciation or from a growth point of view in the pharma industry."